Tirzepatide is the first FDA-approved dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
More serious but less common side effects require prompt medical attention
By targeting both GLP-1 and GIP receptors, tirzepatide delivers stronger appetite regulation and metabolic improvements compared to single-hormone therapies
Sometimes it's a sign that something else, like unmanaged reflux or a bacterial overgrowth, needs attention
Whilst skin sensitivity has not been confirmed as a primary safety signal in published Phase 2 data, some trial participants have reported injection site reactions and other skin-related symptoms
You will be charged $600 every 28 days for the first 6 months and after each charge, we will ship 4 prefilled syringes to you for your once per week injection or we will submit a prescription to the pharmacy of your choice that has the medication and dosage in stock